User:Rosslu2015/sandbox

Profile

HitGen is a rapidly growing biotech company with headquarters and main research facilities based in Chengdu, China, and with a subsidiary in the USA. HitGen has established a platform for small molecule drug discovery research centered on the design, synthesis and screening of DNA encoded chemical libraries (DELs). HitGen's DELs contain over 400 billion novel, diverse, drug-like small molecule and macrocyclic compounds. These compounds are members of DELs synthesised from hundreds of distinct chemical scaffolds, designed with tractable chemistry, and yielded proven results for the discovery of small molecule leads against precedent and unprecedented classes of biological targets. HitGen collaborates with pharmaceutical, biotech, and chemical companies as well as foundations and research institutes in North America, Europe, Asia and Africa to discover and develop approaches for novel medicines and other solutions. HitGen's novel small molecule inhibitor for Class I/IIb HDAC, HG146 (Category 1 of new chemical drug) has started Phase I clinical trials for Multiple Myeloma.